Published in Biotech Business Week, January 10th, 2005
The agreement also includes 5-year warrants to purchase an additional 2,116,666 shares of the company's common stock at an exercise price of $3.00 per share by the investors. Rodman & Renshaw, LLC, served as the placement agent for the transaction.
Roger Stoll, PhD, chairman and CEO of Cortex, stated, "With this financing, Cortex for the first time in its history has the kind of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.